As pertains to CLL, we did not find a benefit from DEMs blockade in MEC‐1 and PCL‐12, expressing inconsistent levels of CD24 if compared to primary human CLL samples, which in turn showed higher CD24 levels and remarkable sensitivity to DEMs targeting (Figure 4; Figure S8). Here, CD24 is linked to B-cell chronic lymphocytic leukemia.